Ezydapa M 10mg/500mg Tablet ER is a combination oral medication containing Dapagliflozin 10mg and Metformin 500mg, designed for the effective management of type 2 diabetes mellitus. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, works by preventing glucose reabsorption in the kidneys, promoting its excretion through urine, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose production, contributing to better glycemic control. The extended-release (ER) formulation ensures a gradual release of the active ingredients, enhancing patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with metformin. Ezydapa M is indicated for patients inadequately controlled on diet and exercise alone or those already on metformin therapy requiring additional glycemic control. It is essential to use this medication under medical supervision, as it may cause side effects such as urinary tract infections, hypoglycemia (especially when combined with other antidiabetic agents), and gastrointestinal discomfort. Regular monitoring of blood glucose levels, kidney function, and overall metabolic parameters is recommended during treatment. Ezydapa M offers a convenient and effective option for managing blood sugar levels in adults with type 2 diabetes, supporting improved long-term outcomes and quality of life.